The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer

Albanese, 2012, The effect of nanoparticle size, shape, and surface chemistry on biological systems, Annu. Rev. Biomed. Eng., 14, 1, 10.1146/annurev-bioeng-071811-150124 Aslakson, 1992, Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor, Cancer Res., 52, 1399 Bai, 2006, Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS), J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci., 831, 169, 10.1016/j.jchromb.2005.11.044 Bauer, 2007, Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry, Cancer, 109, 1721, 10.1002/cncr.22618 Budha, 2012, Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?, Clin. Pharmacol. Ther., 92, 203, 10.1038/clpt.2012.73 Burris, 2009, A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies, Clin. Cancer Res., 15, 6702, 10.1158/1078-0432.CCR-09-0369 Collins, 2009, Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers, Am. J. Surg. Pathol., 33, 1093, 10.1097/PAS.0b013e31819c1c93 Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N. Engl. J. Med., 351, 337, 10.1056/NEJMoa033025 Desai, 2006, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel, Clin. Cancer Res., 12, 1317, 10.1158/1078-0432.CCR-05-1634 Elzoghby, 2012, Albumin-based nanoparticles as potential controlled release drug delivery systems, J. Control. Release, 157, 168, 10.1016/j.jconrel.2011.07.031 Gumuskaya, 2010, EGFR expression and gene copy number in triple-negative breast carcinoma, Cancer Genet. Cytogenet., 203, 222, 10.1016/j.cancergencyto.2010.07.118 Gunther, 2003, Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids, Br. J. Cancer, 88, 463, 10.1038/sj.bjc.6600711 Haffty, 2006, Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer, J. Clin. Oncol., 24, 5652, 10.1200/JCO.2006.06.5664 Jain, 2010, Delivering nanomedicine to solid tumors, Nat. Rev. Clin. Oncol., 7, 653, 10.1038/nrclinonc.2010.139 Kaur, 2012, A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease, BMC Cancer, 12, 120, 10.1186/1471-2407-12-120 Kratz, 2008, Albumin as a drug carrier: design of prodrugs: drug conjugates and nanoparticles, J. Control. Release, 132, 171, 10.1016/j.jconrel.2008.05.010 Martin, 2012, Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features, Histol. Histopathol., 27, 785 Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387 Medina, 2008, Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases, Clin. Ther., 30, 1426, 10.1016/j.clinthera.2008.08.008 Mi, 2004, Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior, J. Biol. Chem., 279, 46659, 10.1074/jbc.M407952200 Nakajima, 2014, Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer, Breast Cancer, 21, 66, 10.1007/s12282-012-0354-1 Nielsen, 2004, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin. Cancer Res., 10, 5367, 10.1158/1078-0432.CCR-04-0220 Park, 2014, High EGFR gene copy number predicts poor outcome in triple-negative breast cancer, Mod. Pathol., 27, 1212, 10.1038/modpathol.2013.251 Pulaski, 1998, Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines, Cancer Res., 58, 1486 Reis-Filho, 2006, EGFR amplification and lack of activating mutations in metaplastic breast carcinomas, J. Pathol., 209, 445, 10.1002/path.2004 Sebak, 2010, Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis, Int. J. Nanomed., 5, 525 Stewart, 2014 Tan, 2008, Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients, Breast Cancer Res. Treat., 111, 27, 10.1007/s10549-007-9756-8 Tao, 2008, Imagable 4T1 model for the study of late stage breast cancer, BMC Cancer, 8, 228, 10.1186/1471-2407-8-228 Tevaarwerk, 2009, Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer, Clin. Ther., 31 Pt 2, 2332, 10.1016/j.clinthera.2009.11.029 Xia, 2002, Anti-tumor activity of GW57: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways, Oncogene, 21, 6255, 10.1038/sj.onc.1205794 Zhang, 2014, EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma, Biomaterials, 35, 4133, 10.1016/j.biomaterials.2014.01.071